125 related articles for article (PubMed ID: 38052324)
21. Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology.
Minato A; Murooka K; Okumura Y; Takaba T; Higashijima K; Nagata Y; Tomisaki I; Harada K; Fujimoto N
In Vivo; 2024; 38(2):873-880. PubMed ID: 38418119
[TBL] [Abstract][Full Text] [Related]
22. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
23. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
Moschini M; Shariat SF; Rouprêt M; De Santis M; Bellmunt J; Sternberg CN; Tombal B; Collette L
J Urol; 2018 May; 199(5):1149-1157. PubMed ID: 29158104
[TBL] [Abstract][Full Text] [Related]
24. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
Rouprêt M; Seisen T; Birtle AJ; Capoun O; Compérat EM; Dominguez-Escrig JL; Gürses Andersson I; Liedberg F; Mariappan P; Hugh Mostafid A; Pradere B; van Rhijn BWG; Shariat SF; Rai BP; Soria F; Soukup V; Wood RG; Xylinas EN; Masson-Lecomte A; Gontero P
Eur Urol; 2023 Jul; 84(1):49-64. PubMed ID: 36967359
[TBL] [Abstract][Full Text] [Related]
25. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
Audenet F; Isharwal S; Cha EK; Donoghue MTA; Drill EN; Ostrovnaya I; Pietzak EJ; Sfakianos JP; Bagrodia A; Murugan P; Dalbagni G; Donahue TF; Rosenberg JE; Bajorin DF; Arcila ME; Hechtman JF; Berger MF; Taylor BS; Al-Ahmadie H; Iyer G; Bochner BH; Coleman JA; Solit DB
Clin Cancer Res; 2019 Feb; 25(3):967-976. PubMed ID: 30352907
[TBL] [Abstract][Full Text] [Related]
26. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.
Margulis V; Puligandla M; Trabulsi EJ; Plimack ER; Kessler ER; Matin SF; Godoy G; Alva A; Hahn NM; Carducci MA; Hoffman-Censits J;
J Urol; 2020 Apr; 203(4):690-698. PubMed ID: 31702432
[TBL] [Abstract][Full Text] [Related]
27. [Preoperative chemotherapy for patients with upper tract urothelial carcinoma: Impact on renal function].
Gabriel PE; Lambert T; Dumont C; Gauthier H; Masson-Lecomte A; Culine S
Prog Urol; 2023 Aug; 33(8-9):446-455. PubMed ID: 37414668
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
Birtle A; Johnson M; Chester J; Jones R; Dolling D; Bryan RT; Harris C; Winterbottom A; Blacker A; Catto JWF; Chakraborti P; Donovan JL; Elliott PA; French A; Jagdev S; Jenkins B; Keeley FX; Kockelbergh R; Powles T; Wagstaff J; Wilson C; Todd R; Lewis R; Hall E
Lancet; 2020 Apr; 395(10232):1268-1277. PubMed ID: 32145825
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
30. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
Posada JM; Yakirevich E; Kamat AM; Sood A; Jacob JM; Bratslavsky G; Grivas P; Spiess PE; Li R; Necchi A; Mega AE; Golijanin DJ; Pavlick D; Huang RSP; Lin D; Danziger N; Sokol ES; Sivakumar S; Ross JS; Cheng L
Mod Pathol; 2024 Mar; 37(3):100424. PubMed ID: 38219954
[TBL] [Abstract][Full Text] [Related]
31. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
Hsieh MC; Chiang PH; Rau KM; Chen YY; Su YL; Huang CH
Urol Oncol; 2015 Nov; 33(11):495.e9-495.e14. PubMed ID: 26254698
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.
Kojima Y; Takahi Y; Ichimaru N; Okumi M; Takahara S; Nonomura N
BMC Res Notes; 2015 Feb; 8():25. PubMed ID: 25648269
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.
Niedersüss-Beke D; Puntus T; Kunit T; Grünberger B; Lamche M; Loidl W; Böhm R; Kraischits N; Kudlacek S; Schramek P; Meran JG
Oncology; 2017; 93(1):36-42. PubMed ID: 28399521
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma.
Li H; Zhou J; Chen R; Zhu J; Wang J; Wen R
Urol Oncol; 2023 Aug; 41(8):356.e1-356.e9. PubMed ID: 37331821
[TBL] [Abstract][Full Text] [Related]
35. Trop-2 in Upper Tract Urothelial Carcinoma.
Tomiyama E; Fujita K; Nakano K; Kuwahara K; Minami T; Kato T; Hatano K; Kawashima A; Uemura M; Takao T; Fushimi H; Katayama K; Imoto S; Yoshimura K; Imamura R; Uemura H; Nonomura N
Curr Oncol; 2022 May; 29(6):3911-3921. PubMed ID: 35735421
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
Soga N; Arima K; Sugimura Y
Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
[TBL] [Abstract][Full Text] [Related]
38. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
[TBL] [Abstract][Full Text] [Related]
39. The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
Zhang J; Yang M; Wei D; Zhang D; Chen Z; Zhu H
BMC Cancer; 2024 Feb; 24(1):202. PubMed ID: 38350941
[TBL] [Abstract][Full Text] [Related]
40. Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Pham MN; Apolo AB; De Santis M; Galsky MD; Leibovich BC; Pisters LL; Siefker-Radtke AO; Sonpavde G; Steinberg GD; Sternberg CN; Tagawa ST; Weizer AZ; Woods ME; Milowsky MI
World J Urol; 2017 Mar; 35(3):367-378. PubMed ID: 27342991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
